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Angiogenesis, the formation of new blood ves-
sels from preexisting vasculature, is a tightly 
regulated  physiological  process  required  for 
embryonic development (Breier, 2000), repro-
ductive function (Fraser and Lunn, 2000), and 
wound healing (Tonnesen et al., 2000). Angio-
genesis is also a key factor in the pathogenesis of 
several clinical conditions, including ocular dis-
eases, such as age-related macular degeneration 
(Kulkarni and Kuppermann, 2005), diabetic 
retinopathy (Gardner et al., 2002), and corneal 
graft failure (Price et al., 2003), and nonocular 
diseases, such as cancer (Carmeliet and Jain, 
2000) and rheumatoid arthritis (Koch, 1998). 
The process begins when the endothelial cells 
of a mature blood vessel wall are activated by 
angiogenic  factors,  that  include,  but  are  not 
limited to, basic fibroblast growth factor (bFGF) 
and  the  vascular  endothelial  growth  factor 
(VEGF) families of cytokines (Cross and Claesson- 
Welsh, 2001). Activation promotes the loosening 
of endothelial cells from their basement mem-
brane and the supporting periendothelial cells, 
thereby allowing them to migrate, proliferate, 
and ultimately form a capillary lumen, which is 
stabilized by pericytes and smooth muscle cells.
Galectin-3  is  a  member  of  the  galectin 
family of mammalian lectins characterized by 
a conserved sequence within the carbohydrate 
recognition domain (CRD) that has affinity 
for  -galactoside  structures.  Extracellularly, 
the lectin is assumed to mediate cell–cell and 
cell–matrix interactions by binding to lactos-
amine-containing cell surface glycoconjugates 
via the CRD. Recently, galectin-3 has been 
implicated  in  the  process  of  angiogenesis. 
Studies by Nangia-Makker et al. (2000) have 
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Recent studies have shown that a carbohydrate-binding protein, galectin-3, is a novel  
pro-angiogenic molecule. The mechanism by which galectin-3 promotes angiogenesis 
remains unknown. We demonstrate here that galectin-3 is a mediator of vascular endothe-
lial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-mediated angiogenic 
response. Angiogenesis assays revealed that galectin-3 inhibitors, -lactose and dominant-
negative galectin-3, reduce VEGF- and bFGF-mediated angiogenesis in vitro and that 
VEGF- and bFGF-mediated angiogenic response is reduced in galectin-3 knockdown cells 
and Gal3/ animals. Integrin v3 was identified as the major galectin-3–binding protein 
and anti-v, -3, and -v3 integrin function-blocking antibodies significantly inhibited 
the galectin-3–induced angiogenesis. Furthermore, galectin-3 promoted the clustering of 
integrin v3 and activated focal adhesion kinase. Knockdown of GnTV, an enzyme that 
synthesizes high-affinity glycan ligands for galectin-3, substantially reduced: (a) complex 
N-glycans on v3 integrins and (b) VEGF- and bFGF-mediated angiogenesis. Collectively, 
these data suggest that galectin-3 modulates VEGF- and bFGF-mediated angiogenesis by 
binding via its carbohydrate recognition domain, to the GnTV synthesized N-glycans of 
integrin v3, and subsequently activating the signaling pathways that promote the 
growth of new blood vessels. These findings have broad implications for developing novel, 
carbohydrate-based therapeutic agents for inhibition of angiogenesis.
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the mouse corneal micropocket assay. The vessel area, repre-
senting the extent of angiogenesis, was calculated 5 d after 
pellets containing various concentrations of galectin-3 were 
implanted in the mouse corneas. In the concentration range 
tested (20–160 ng galectin-3/pellet), the extent of angiogen-
esis increased in a dose-dependent manner up to 80 ng/pellet. 
At concentrations >80 ng/pellet, there was no further in-
crease in the degree of angiogenesis (Fig. 1 A; Vessel Area, 
Control [n = 16; 0.14 ± 0.051 mm2]; Galectin-3: 20 ng   
[n = 4; 0.64 ± 0.225 mm2], 40 ng [n = 4; 0.82 ± 0.195 mm2], 
80 ng [n = 10; 1.86 ± 0.225 mm2], and 160 ng [n = 4; 1.57 ± 
0.15 mm2]).
Galectin-3 (30 kD) is made up of a C-terminal CRD, 
a collagen-like internal R-domain, and the N-terminal domain 
that promotes oligomerization of the lectin. Cleavage of the 
N-terminal domain by collagenase digestion of R-domain 
gives rise to a 21-kD C-terminal domain of galectin-3 (Gal3C) 
that contains the entire CRD and retains its ability to bind to 
lactosamine-containing glycans. Therefore, Gal3C competes 
with the carbohydrate-binding ability of the endogenous 
galectin-3  and  acts  as  a  dominant-negative  inhibitor  of 
full-length galectin-3. However, because Gal3C lacks the 
N-domain, it is unable to form dimers or higher order oligo-
mers (Hirabayashi et al., 2002; John et al., 2003). To determine 
whether the angiogenic property of galectin-3 is dependent 
on its ability to oligomerize and act in a bi-/multi-valent 
manner, we tested whether Gal3C was able to promote an-
giogenesis in vitro and in vivo. Unlike full-length galectin-3, 
Gal3C failed to induce migration and capillary tubule forma-
tion of endothelial cells in vitro (Fig. 1, B and C) and angio-
genesis in vivo (Fig. 1 D). Moreover, Gal3C effectively 
inhibited  in  vitro  angiogenesis  advanced  by  full-length   
galectin-3 (Fig. 1, B and C; percentage of inhibition: mi-
gration, 95.2 ± 0.003%; capillary tubule formation, 99.6 ± 
0.0002%). These results suggest that multivalent galectin-3 
assembly by the N-terminal domain and the carbohydrate 
recognition  domain  are  both  required  for  galectin-3– 
mediated angiogenesis.
Galectin-3 promotes angiogenesis by influencing  
the function of VEGF and bFGF in a carbohydrate-
dependent manner
Multiple  approaches  were  used  to  investigate  whether   
galectin-3 influences the function of well-known angiogenic   
molecules, VEGF, and bFGF. First, we tested the effect of 
dominant-negative galectin-3, Gal3C, on VEGF- and bFGF-
induced angiogenesis. Addition of Gal3C completely blocked 
VEGF- and bFGF-mediated endothelial cell migration (Fig. 2 A) 
and capillary tubule formation (Fig. 2 B). This suggests that 
not only is galectin-3 required for VEGF- and bFGF-mediated 
angiogenesis in vitro, but also that galectin-3 multimer for-
mation is necessary for VEGF- and bFGF-mediated angio-
genesis. Both VEGF- and bFGF-induced endothelial cell 
migration and capillary tubule formation were markedly reduced 
by a competing saccharide, -lactose (percentage of reduction: 
cell  migration,  VEGF,  85.15  ±  1.89;  bFGF,  75.53  ±  3.10;   
shown that tumor angiogenesis, induced by subcutaneous 
injections with breast carcinoma cell in an animal model, is sig-
nificantly greater when the carcinoma cells express galectin-3 
as compared with galectin-3–null controls. These authors 
have further shown that exogenous galectin-3 promotes   
endothelial cell migration and capillary tubule formation 
in vitro. The mechanism by which galectin-3 influences an-
giogenesis, however, remains elusive. Binding assays predict 
two receptors on human umbilical vein endothelial cells 
(HUVEC), one of high affinity (Kd = 0.537 × 109) and the 
other of low affinity (Kd = 7.161 × 109; Nangia-Makker   
et al., 2000). The identity of these receptors, however, re-
mains unknown. Yang et al. (2007), using a phage display 
biopanning method, identified galectin-3 as a binding part-
ner for aminopeptidase N/CD13 (APN) in endothelial cells 
and suggested that the lectin may mediate angiogenesis via 
APN. However, because of its short cytoplasmic domain, 
APN is unlikely to singularly initiate galectin-3–mediated 
activation of endothelial cells (Yang et al., 2007). It is not 
known whether galectin-3 promotes angiogenesis indepen-
dently of the action of angiogenic cytokines or whether   
galectin-3 contributes to the function of the known angio-
genic molecules. One study has shown that modified citrus 
pectin (MCP), a galactose-rich polysaccharide that binds 
to galectin-3, and possibly also to other members of the ga-
lectin family, reduces bFGF-mediated migration of endo-
thelial cells, suggesting that one or more members of the 
galectin family may participate in bFGF-mediated angio-
genesis (Nangia-Makker et al., 2002). Thus far, more direct 
studies involving the use of galectin-3 knockout mice and 
cells have not been performed.
In this study, we investigate whether galectin-3 contrib-
utes to VEGF- and bFGF-mediated angiogenesis. We show 
that a decrease in the expression of galectin-3 by siRNA 
knockdown results in the reduction of angiogenic response to 
VEGF and bFGF in vitro and that VEGF- and bFGF-mediated 
angiogenesis in vivo is reduced in Gal3/ mice. We further 
demonstrate that: (a) v3 integrin is the major galectin-3–
binding protein; (b) galectin-3 activates v3 integrin sig-
naling; and (c) carbohydrate-mediated interaction between 
galectin-3 and complex N-glycans on v3 integrin plays a 
key role in galectin-3–mediated angiogenesis.
RESULTS
Galectin-3 promotes angiogenesis in vivo: the C-terminal 
carbohydrate recognition domain and the N-terminal  
self-association domain are required for galectin-3–
mediated angiogenesis
A previous study has shown that galectin-3 promotes migra-
tion and capillary tubule formation of HUVECs in vitro and 
that tumor angiogenesis induced by subcutaneous injections 
with breast carcinoma cells in mice is significantly greater 
when the carcinoma cells express galectin-3 compared with 
galectin-3–null cells (Nangia-Makker et al., 2000). Here, we 
show that galectin-3 directly promotes angiogenesis in vivo. 
Galectin-3–mediated angiogenesis in vivo was evaluated by JEM VOL. 207, August 30, 2010 
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restored VEGF- and bFGF-mediated angiogenesis (Fig. 3, 
C and D, Rescue), supporting the hypothesis that galectin-3   
is an important contributor in VEGF- and bFGF-medi-
ated angiogenesis.
As a direct test of the role of galectin-3 in VEGF- and 
bFGF-mediated angiogenesis in vivo, we performed mouse 
corneal  micropocket  assays  in  Gal3/  and  Gal3+/+  
animals. Pellets containing either 100 ng VEGF or 20 ng 
bFGF were implanted into mouse corneas and, 5 d after 
surgery, the animals were perfused with an endothelial cell 
marker, FITC-Bandeiraea simplicifolia lectin I (BS1), to vi-
sualize the vessels. Control pellets, which did not contain 
any protein, did not promote angiogenesis (unpublished 
data). In Gal3+/+ mice, both VEGF and bFGF induced ro-
bust corneal neovascularization (Fig. 4). The extent of ves-
sel formation mediated by VEGF and bFGF was significantly 
reduced in Gal3/ animals as compared with Gal3+/+ ani-
mals; specifically, fewer branching capillaries were seen in 
the Gal3/ corneas (Fig. 4). Vessel density as assessed by 
quantifying the vessel-occupied area, was markedly lower 
in the Gal3/ corneas as compared with the Gal3+/+ cor-
neas (Fig. 4; percentage of reduction: VEGF, 58.2 ± 10.5; 
bFGF, 29.2 ± 7.3).
capillary  tubule  formation,  VEGF,  80.46  ±  6.40;  bFGF, 
86.36 ± 5.91). In contrast, a noncompeting disaccharide, su-
crose, had no effect. The inhibition was not a result of de-
creased cell viability. As assessed by trypan blue exclusion, 
cell viability was unchanged in the presence of saccharides 
(unpublished data). These data suggest galectin-3–mediated 
carbohydrate-based recognition also plays a role in the VEGF- 
and bFGF-induced angiogenesis.
To further evaluate the role of galectin-3 in growth   
factor-mediated  angiogenesis,  expression  of  endogenous 
galectin-3 was reduced in HUVECs by siRNA-mediated 
knockdown. Galectin-3–specific siRNA reduced the ex-
pression of galectin-3 mRNA (Fig. 3 A) and protein (Fig. 3 B) 
by 70 and 64%, respectively. A nontargeting siRNA had 
no effect on galectin-3 mRNA and protein levels (Fig. 3,   
A and B). Neither galectin-3 nor nontargeting siRNA in-
duced  a  nonspecific  knockdown  of  -actin  (Fig.  3  B). 
Knockdown of endogenous galectin-3 markedly reduced 
the extent of VEGF- and bFGF-mediated cell migration 
(Fig.  3  C;  percentage  of  reduction:  VEGF,  46.3  ±  5.9; 
bFGF, 39.7 ± 4.1) and capillary tubule formation in vitro 
(Fig.  3  D;  percentage  of  reduction:  VEGF,  70.9  ±  5.4; 
bFGF, 50.12 ± 4.57). The addition of exogenous galectin-3 
Figure 1.  Galectin-3 promotes angio-
genesis in vivo in a dose-dependent man-
ner. (A) Angiogenesis in vivo was evaluated 
using the mouse corneal micropocket assay. 
Sustained-release polymer pellets containing 
various doses of galectin-3 (20–160 ng/pellet) 
were implanted in the corneas of Gal3+/+ ani-
mals. (i) 5 d after surgery, the vessel area was 
calculated as described in the text. Data are 
expressed as mean ± SEM (n = 4 or more).  
*, P < 0.01 compared with control pellets (Con) 
without any protein. (ii) Representative fluo-
rescence images of corneas are shown in A (i). 
White asterisks indicate pellets. (B–D) Full-
length galectin-3 but not truncated galectin-3  
(Gal3C) promotes angiogenesis in vitro and  
in vivo. (B) Modified Boyden Chamber Assay. 
The cells that migrated from the upper cham-
ber to the lower chamber during the period of 
6 h in response to the protein gradients cre-
ated by full-length galectin-3 and/or Gal3C 
were counted in three nonoverlapping fields 
under a microscope (320×). Data are ex-
pressed as mean ± SEM (n = 3/group).  
*, P < 0.01 compared with cells incubated with 
media alone (Con). (C) Capillary tubule forma-
tion assay. HUVECs premixed with galectin-3 
and/or Gal3C were plated on solidified matrigel 
(4.5 mg/ml) and after 6-h incubation, the 
extent of capillary tubule formation was eval-
uated by counting the number of branch 
points. Data are expressed as mean ± SEM (n = 3 or more/group). *, P < 0.01 compared with cells incubated with media alone (Con). (D) Angiogenesis  
in vivo was evaluated using the mouse corneal micropocket assay using pellets containing full-length (Gal3) and truncated galectin-3 (Gal3C; 80 ng/
pellet). Data are expressed as mean ± SEM (n = 4 or more). *, P < 0.01 compared with control pellets (Con). Representative fluorescence images of corneas 
are shown in D (ii). White asterisks indicate pellets. Bars, 200 µm. Data are representative of three or more independent experiments.1984 Galectin-3 influences VEGF and bFGF-mediated angiogenesis | Markowska et al.
anti-v and anti-3 mAbs on galectin-3–induced angiogene-
sis; the ability of galectin-3 to promote v3 integrin cluster-
ing and subsequent activation of signaling pathways; and the 
function of galectin-3 in the context of glycosylation pattern 
of v3 integrin.
Anti-v3 integrin antibodies inhibit galectin-3–mediated 
angiogenesis.  To  determine  whether  v3  integrin  is   
involved in galectin-3–induced angiogenesis, HUVE cell mi-
gration and capillary tubule formation assays were performed 
using cells pretreated with, and in the presence of, function-
blocking anti-v (clone AV1), anti-3 (clone B3A), or anti-
v3 (LM609) integrin mAbs. Addition of each of the three 
antibodies  significantly  inhibited  galectin-3–mediated  cell 
migration and capillary tubule formation (Fig. 5, B and C; 
percentage of reduction: migration, 67.1 ± 5.02% [v], 59.8 ± 
7.12% [3], and 66.7 ± 4.71% [v3]; capillary tubule for-
mation, 63.1 ± 9.0% [v], 62.7 ± 17.3% [3], and 54.8 ± 
13.5% [v3]). These data suggest that integrin v3 is a sig-
nificant player in the cascade of events involved in galectin-3– 
induced angiogenesis.
Galectin-3 promotes clustering of integrin v3 and ac-
tivation of focal adhesion kinase (FAK). To determine 
Galectin-3 influences VEGF- and bFGF-mediated 
angiogenesis by modulating the activity of v3 integrin
v3 integrin is the major galectin-3–binding protein in 
endothelial  cells. To define the molecular mechanism by 
which galectin-3 induces angiogenesis, information on its 
binding partners is prerequisite. To identify galectin-3– 
specific binding partners, HUVE cell lysates were chromato-
graphed on a galectin-3–affinity column and bound proteins, 
eluted with -lactose, were electrophoresed and character-
ized. Matrix-assisted laser desorption ionization time of flight 
(MALDI-TOF) mass spectrometry analysis revealed that the 
fraction eluted from the galectin-3–affinity column contained 
several proteins including v and 3 integrin subunits (num-
ber of peptides matched: integrin v, 9 peptides [Fig. S1 A], 
integrin 3, 5 peptides [Fig. S1 B]) that have been shown to 
play a key role in VEGF- and bFGF-mediated angiogenesis 
(Brooks, 1994, 1996; Drake et al., 1995; Friedlander et al., 
1995; Storgard et al., 1999; Hodivala-Dilke et al., 2003). Also, 
in Western blot analysis, 125-kD anti-v and 104-kD anti-3 
integrin-reactive  components  were  detected  in  the  bound 
fraction eluted from the galectin-3 column by -lactose but 
not in the fraction eluted with sucrose (Fig. 5 A). In an effort 
to characterize the role of v3 integrin in the galectin-3– 
mediated angiogenesis, we further investigated: the effect of 
Figure 2.  Galectin-3 inhibitors block 
VEGF- and bFGF-mediated angiogenesis  
in vitro. (A) Modified Boyden chamber assay. 
The effect of galectin-3 inhibitors on VEGF- 
and bFGF-induced cell migration was evalu-
ated. The cells that migrated from the upper 
chamber to the lower chamber were counted 
as described in Fig. 1. (B) Capillary tubule 
formation assay. HUVEC suspensions pre-
mixed with cytokines were plated on solidified 
matrigel (4.5 mg/ml), and, after 6-h incuba-
tion, the extent of capillary tubule formation 
was evaluated by counting the number of 
branch points. Representative images from 
each group are shown in B (ii). Images of cells 
incubated in media alone (not depicted) were 
indistinguishable from those incubated in 
media containing VEGF or bFGF in the pres-
ence of -lactose (Lac). The assays were per-
formed in the absence (Control) and presence 
of truncated galectin-3 (Gal3C, a dominant-
negative inhibitor of galectin-3), full-length 
galectin-3 (Gal3), 0.1 M -lactose (Lac, a 
competing saccharide), and 0.1 M sucrose 
(Suc, a noncompeting control saccharide). 
Data are expressed as mean ± SEM (n = 3 or 
more/group), *, P < 0.01; **, P < 0.05 com-
pared with respective controls incubated 
without galectin-3 inhibitors (Control) or with 
a noncompeting saccharide (Suc). Bar, 100 µm. 
Data are representative of three or more inde-
pendent experiments.JEM VOL. 207, August 30, 2010 
Article
1985
time-dependent  activation  of  phosphorylated  FAK 
(pFAK). FAK became phosphorylated within 2 min after 
treatment with galectin-3 and remained active for the en-
tire 10 min (Fig. 5 E). At the same time, the total FAK levels 
remained unchanged. These data lead us to conclude that 
galectin-3–induced v3 integrin clustering promotes FAK 
activation, an event that most likely modulates galectin-3–
mediated angiogenesis.
A  reduction  in  1,6GlcNAc-branched  N-glycans  on 
v3 integrin abolishes the ability of galectin-3 to pro-
mote angiogenesis. To evaluate the importance of a galectin-3– 
v3 integrin glycan interaction in galectin-3–mediated 
angiogenesis, the expression of N-acetylglucosaminyltrans-
ferase V (GnTV), an enzyme that synthesizes N-glycan in-
termediates that are elongated with N-acetyllactosamines 
to create high-affinity ligands for galectin-3, was disrupted. 
whether  galectin-3  promotes  clustering  of  integrin  v3, 
cells were treated with galectin-3 (10 µg/ml) for 10 min and 
then subjected to confocal microscopy. Cells exposed to   
galectin-3 demonstrated distinct punctuate staining throughout 
the cell body, which is indicative of integrin clustering   
(Fig. 5 D). In contrast, cells exposed to media alone exhibited 
weak, diffuse staining with occasional microclustering.
Because integrin clustering has been shown to trigger in-
tracellular signaling via FAK activation (Parsons, 2003), and 
FAK signaling has been implicated in the process of angio-
genesis (Ilic et al., 1995, 2004; Shen et al., 2005; Braren et al., 
2006), it was of interest to determine whether stimulation of 
endothelial cells with galectin-3 would result in FAK activa-
tion. To investigate whether galectin-3 activated FAK, the 
phosphorylation  status  of  FAK  in  HUVECs  treated  with   
10 µg/ml galectin-3 for 30 s, 1, 2, 5, and 10 min was examined 
by immunoblot analysis. Treatment with galectin-3 induced 
Figure 3.  Galectin-3 knockdown reduces VEGF- and bFGF-mediated angiogenesis in vitro. (A and B) HUVECs were transfected with siRNA du-
plexes directed against galectin-3 (Gal3 siRNA) or control nontargeting siRNA duplexes (Control siRNA). The knockdown of galectin-3 was evaluated by 
RT-qPCR (A) and Western blot analysis (Bi: a representative image, Bii: quantification of protein knockdown by ImageJ). (C and D) VEGF and bFGF induced 
cell migration and capillary tubule formation is reduced in galectin-3–knockdown cells. The ability of 25 ng/ml VEGF (open bars) and 10 ng/ml bFGF (solid 
bars) to promote chemotaxis (C) and capillary tubule formation (D) in galectin-3 siRNA (Gal3 siRNA) transfected and nontargeting siRNA-transfected 
(control siRNA) HUVECs, as well as galectin-3 siRNA transfected HUVECs in the presence of 10 µg/ml exogenous galectin-3 (Rescue) was compared.  
A value of 1.0 was assigned to cell migration and capillary tubule formation values of control cells. The values of all other cells were calculated as a fold 
change with respect to control cells. Data are expressed as mean ± SEM (n = 3/group). *, P < 0.01 and **, P < 0.05 as compared with nontargeting siRNA 
transfected HUVECs). Representative images of the cells that migrated from the upper chamber to the lower chamber and capillary tubule formation in 
response to VEGF and bFGF stimulation are shown in C (ii) and D (ii), respectively. Bars: (C, ii) 100 µm; (D; ii) 200 µm. Data are representative of two or 
more independent experiments.1986 Galectin-3 influences VEGF and bFGF-mediated angiogenesis | Markowska et al.
pattern of noninfected control and GnTV shRNA expressing 
cells were similar. Although galectins lack transmembrane   
domains, secreted galectins associate with the cell surface by 
binding to plasma membrane glycoproteins. To determine 
whether GnTV knockdown resulted in the reduction of   
galectin-3 counterreceptors on the cell surface, the cell surface 
proteins of HUVECs transfected with lentiviral particles ex-
pressing shRNA directed against GnTV (shGnTV) or nontar-
geting  shRNA  control  (shControl)  were  biotinylated  and 
cross-linked in a single step. The biotinylated proteins were 
isolated  by  streptavidin  pull-down,  treated  with  Laemmli 
sample buffer to release individual proteins of linked com-
plexes, electrophoresed in reducing conditions, and then probed 
with anti-galectin-3 mAb. In the streptavidin pull-down   
fraction (PD; Strep), a reduced level of the 30-kD anti-
galectin-3–reactive component was detected in the GnTV 
knockdown cells compared with the control cells transfected 
with nontargeting lentiviral particles (Fig. 6 C). This sug-
gests that GnTV knockdown reduces the expression of glyco-
protein counterreceptors of galectin-3 on the endothelial   
cell surface.
To determine whether 1,6GlcNAc-branched N-glycans 
on v and 3 integrin subunits were reduced in GnTV shRNA–
expressing cells, pull-down experiments were conducted 
using agarose-conjugated plant lectins (L-PHA and con-
canavalin A [ConA]) and the proteins bound to the lectins 
were analyzed for reactivity with anti-v and anti-3 inte-
grin antibodies by Western blot analysis. Both v and 3 
integrins from GnTV shRNA–expressing cells showed a 
significant reduction in l-PHA binding (Fig. 6 D, lane M) 
compared with noninfected (Fig. 6 D, lane H) and non– 
target shRNA–expressing cells (Fig. 6 D, lane C). In con-
trast, the binding of integrins to a control lectin, ConA, was 
not affected (Fig. 6 D). These data indicate that the knock-
down  of  GnTV  gene  expression  leads  to  a  significant   
reduction in 1,6GlCNAc-branched N-glycans on v and 
3 integrin subunits.
Next,  we  determined  whether  reduced  GnTV  en-
zyme product on N-glycans of v and 3 integrins hin-
ders  galectin-3  and/or  growth  factor-induced  angiogenesis   
in vitro. Indeed, galectin-3, VEGF, and bFGF failed to promote 
cell migration (Fig. 6 E) and capillary tubule formation 
(Fig. 6 F) of endothelial cells in which GnTV expression 
was reduced. In contrast, there was no difference in the 
extent of galectin-3 and growth factor–mediated migra-
tion and capillary tubule formation between noninfected 
and non–target shRNA–expressing cells. Galectin-3, and 
growth factors, also failed to advance angiogenesis in vivo 
in GnTV/ animals, whereas it led to robust angiogenesis 
in GnTV+/+ animals (Fig. 6 G). These data support the 
concept that GnTV modified complex N-glycans on inte-
grin v and 3 play a role in galectin-3–mediated angio-
genesis. Moreover, as expected, the decrease in VEGF- and 
FGF-induced cell migration and capillary tubule forma-
tion seen in the GnTV knockdown cells could not be res-
cued by exogenous galectin-3 (unpublished data). These 
The effect of GnTV knockdown was assessed on the follow-
ing factors: binding of galectin-3 to cell surface glycoprotein 
receptors; v and 3 integrin glycans; and galectin-3 and 
growth factor-induced angiogenesis.
The expression of GnTV was knocked down by transfec-
tion of HUVECs with shRNA constructs directed against 
GnTV. As controls, HUVECs were transfected with constructs 
expressing a nontargeting sequence. The loss of N-glycan   
intermediates synthesized by GnTV was confirmed by the loss 
of the ability of cells to bind FITC-labeled Phaseolus vulgaris 
leukoagglutinin (L-PHA) lectin, which reacts specifically   
with core 1,6-branched products synthesized by GnTV 
(Cummings and Kornfeld, 1982). The knockdown of GnTV 
at the mRNA level was analyzed by RT-qPCR. Transfection 
of HUVECs with shRNA constructs directed against GnTV 
resulted in a substantial knockdown (>80%) of GnTV mRNA 
expression (Fig. 6 A) and synthesis of GnTV products (Fig. 6 B) 
as compared with untransfected cells and cells transfected with 
a nontargeting control construct. The morphology and growth 
Figure 4.  VEGF- and bFGF-induced angiogenesis is reduced in 
Gal3/ mice. Angiogenesis in vivo was evaluated using the mouse cor-
neal micropocket assay as described in the text using VEGF and bFGF 
pellets. 5 d after surgery, the animals were perfused with FITC-BS1, and 
the extent of angiogenesis was evaluated by examining the flat mounts  
of corneas by fluorescence microscopy. Blood vessel area was calculated 
using ImageJ. (A) Vessel area of neovascularization expressed in pixel2 × 104. 
Data are expressed as mean ± SEM (n = >4/group). *, P < 0.05 com-
pared with Gal3+/+ control animals. (B) Representative fluorescence im-
ages of corneas. White asterisks indicate pellets. Bar, 200 µm. Data are 
representative of two independent experiments.JEM VOL. 207, August 30, 2010 
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have suggested that cross-linking of galectin-3–binding glycans 
present on cell surface receptors (e.g., epidermal growth factors 
and 51 integrin) provides a potential mechanism by which 
galectin-3 mediates its action (Partridge et al., 2004; Lagana   
et al., 2006). That the multimeric form of the lectin is required 
for  galectin-3–induced  angiogenesis  is  demonstrated  by  our 
findings that, unlike full-length galectin-3, Gal3C, that is unable 
to form dimers or higher order oligomers (Hirabayashi et al., 
2002; John et al., 2003), is not angiogenic. In our study Gal3C 
not only failed to induce angiogenesis, it effectively inhibited 
the angiogenesis induced by full-length galectin-3. This suggests 
that Gal3C which contains the entire CRD and retains the abil-
ity to bind to lactosamine-containing glycans effectively com-
peted with endogenous full-length galectin-3 and that CRD 
and the carbohydrate binding property of the lectin is also re-
quired for the angiogenic activity of the lectin. These findings 
are consistent with the report of Nangia-Makker et al. (Nangia-
Makker et al., 2000) showing that -lactose and galactose-rich   
data lead us to conclude that interactions between GnTV-
modified  glycans  and  galectin-3  are  required  for  the 
growth factor–mediated angiogenesis.
DISCUSSION
This  study  was  undertaken  to  examine  the  mechanism  by 
which galectin-3 mediates angiogenesis. We demonstrate 
here that both the C-terminal CRD and the N-terminal self-
associating domain of the lectin are required for galectin-3– 
mediated angiogenesis. In the presence of its multivalent sac-
charide  ligands,  galectin-3  forms  multimer  via  the  associa-
tion of single galectin-3 molecules at the N terminus (Ahmad   
et al., 2004). This allows the lectin to function in a multiva-
lent fashion and cross-link many cell surface and extracellular 
matrix (ECM) glycoproteins, such as integrins, growth factor 
receptors, laminins, and vitronectin (Ohannesian et al., 1995; 
Dong and Hughes, 1997; Matarrese et al., 2000; Partridge et al., 
2004; Lagana et al., 2006; Stillman et al., 2006). Recent studies 
Figure 5.  Integrin v3 serves as a galectin-3 counter-receptor. (A) HUVEC lysates were applied to a galectin-3 affinity chromatography column 
and bound proteins were sequentially eluted with a noncompeting saccharide, 0.1 M sucrose (Suc), and a competing saccharide, 0.1 -lactose (Lac). 
Proteins eluted from the affinity column were identified by Western blot analysis. Both v and 3 integrins were detected in the lactose eluate, but not 
in the sucrose eluate. (B and C) Integrin-blocking antibodies directed against integrins v, 3, and v3 inhibit galectin-3–induced cell migration (B) and 
capillary tubule formation (C). The ability of 10 µg/ml galectin-3 to promote chemotaxis (Boyden chamber assay) and capillary tubule formation in the 
presence and absence of 10 µg/ml v, 3, and v3 integrin-blocking antibodies or control mouse IgG was compared. Data are expressed as mean fold 
change over control cells incubated in media alone ± SEM (n = 3/group). **, P < 0.05; *, P < 0.01 as compared with cell migration and capillary tubule 
formation induced by galectin-3. (D) Galectin-3 promotes clustering of integrin v3. HUVECs were serum starved overnight and treated with 10 µg/ml 
galectin-3 for 10 min. At the end of the incubation period, the distribution of integrin v3 was evaluated by confocal microscopy after immunostaining 
with an anti–human integrin v3 monoclonal antibody. Treatment with galectin-3 resulted in a marked redistribution of integrins into a punctate  
pattern, indicative of integrin clustering. Overlapping Normanski images are shown on the bottom (NM). Bar, 50 µm. (E) Galectin-3 mediates FAK  
activation. HUVECs were serum starved for 2 h and treated with 10 µg/ml of galectin-3 for various time periods (0, 0.5, 1, 2, 5, and 10 min). HUVEC  
lysates were then subjected to immunoblot analysis for pFAK (Y397; top) and FAK (bottom). Galectin-3 treatment promoted a time-dependent activation 
of FAK that started at 1 min and peaked at 5 min. Total FAK levels remained unchanged at all time periods. Data are representative of three or more  
independent experiments.1988 Galectin-3 influences VEGF and bFGF-mediated angiogenesis | Markowska et al.
studies show that Gal3C, the dominant-negative inhibitor of 
galectin-3, and the saccharide inhibitor of galectin-3, lactose 
(but not a noncompeting disaccharide, sucrose), ameliorated 
VEGF and bFGF angiogenic activity. In addition, silencing of 
polysaccharide,  MCP,  also  inhibit  galectin-3–mediated- 
angiogenesis in vitro.
The major finding of the current study is that galectin-3 
modulates VEGF- and bFGF-mediated angiogenesis. Our 
Figure 6.  Disruption of GnTV reduces binding of galectin-3 to cell surface glycoprotein receptors with a concomitant reduction in galectin-3  
and growth factor-mediated angiogenesis in vitro and in vivo. (A) HUVECs were transfected with lentiviral particles expressing shRNA directed 
against GnTV (shGnTV) or nontargeting shRNA control (shControl). The knockdown of endogenous GnTV was evaluated at the mRNA level by RT-qPCR. 
The value for HUVECs transfected with GnTV and control shRNA is expressed as the change in the expression level with respect to untransfected cells 
which served as a calibrator. *, P < 0.01 compared with control cells. (B) Expression of GnTV product, core  1,6-branched saccharides, in HUVECs trans-
fected with lentiviral particles was evaluated by staining with rhodamine-conjugated l-PHA, which specifically reacts with core  1,6-branched saccha-
rides. Bar, 100 µm. (C) The cell surface proteins of HUVECs transfected with lentiviral particles expressing shRNA directed against GnTV (shGnTV) or 
nontargeting shRNA control (shControl) were biotinylated and cross-linked in a single step, the biotinylated proteins were isolated by streptavidin pull-
down, electrophoresed in reducing conditions and then probed with anti–galectin-3 mAb. Regardless of whether the Western blot analysis was performed 
using the streptavidin pull-down proteins (PD:Strep) or whole-cell lysates (WCL) of the labeled cells, reduced level of galecin-3 was detected in the GnTV 
knockdown cells compared with the cells transfected with control, nontargeting lentiviral particles. (D) GnTV modifies integrins v and 3. RIPA buffer 
cell lysates (WCL) of untransfected HUVECs (H) and HUVECs transfected with control (C) and GnTV (M) targeting lentiviral particles were incubated with 
either l-PHA-agarose or ConA-agarose (1 h at 4°C). Bound proteins were eluted from the agarose beads by boiling in SDS-PAGE sample buffer, separated 
on SDS-PAGE, and immunostained to detect integrins v and 3. Note that GnTV knockdown cell lysates show markedly reduced binding of integrins  
v and 3 to l-PHA indicating that integrins v and 3 are modified by GnTV. (E and F) The ability of galectin-3 (10 µg/ml), VEGF (25 ng/ml), and bFGF 
(10 ng/ml) to promote cell migration (E, Boyden chamber assay) and capillary tubule formation (F) is substantially reduced in GnTV knockdown cells. Data are 
expressed as mean fold change over control cells incubated in media alone ± SEM (n = 3/group), *, P < 0.01; **, P < 0.05 compared with untransfected 
controls. (G) VEGF- and bFGF-induced angiogenesis is reduced in GnTV/ mice. Angiogenesis in vivo was evaluated by the mouse corneal micropocket 
assay using VEGF and bFGF pellets. On day 5 after surgery, the animals were perfused with FITC-BS1, and the extent of angiogenesis was evaluated by 
examining the flat mounts of corneas by fluorescence microscopy. Blood vessel area was calculated using ImageJ. (i) Vessel area of neovascularization 
expressed in pixel2 x 104. Data are expressed as mean ± SEM (n = at least 4/group). *, P < 0.05 compared with GnTV+/+ control animals. (ii) Representative 
fluorescence images of corneas. White asterisks indicate pellets. Bar, 100 µm. Control pellets, which did not contain any protein, did not promote angio-
genesis [not depicted; images identical to that shown in Fig. 1 A (ii)]. Data are representative of two independent experiments each repeated in triplicate.JEM VOL. 207, August 30, 2010 
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cell migration by cross-linking GnTV-modified complex   
N-glycans on 31 integrin and subsequently activating 31 
integrin-Rac1 signaling that regulates lamellipodia formation 
(Saravanan et al., 2009). In an effort to characterize the molec-
ular mechanism by which galectin-3 mediates angiogenesis, in 
the current study, we investigated the function of galectin-3 in 
the context of the glycosylation pattern of v3 integrin. Using 
affinity chromatography on a galectin-3–Sepharose column, 
we identified v and 3 integrin subunits as major galectin-3–
binding proteins in HUVECs. We further demonstrated that 
function-blocking mAbs against v, 3, and v3-integrin 
markedly reduce the ability of the lectin to promote angiogen-
esis. That the angiogenic property of galectin-3 is dependent 
on CRD and the carbohydrate-mediated integrin signaling is 
suggested by our findings that binding of galectin-3 to v and 
3 integrin subunits and the stimulatory effect of galectin-3 on 
angiogenesis was inhibited by a competing sugar, -lactose, 
but not by a noncompeting sugar, sucrose, and that knockdown 
of gene expression of a rate-limiting enzyme, GnTV, resulted in 
the loss of 1,6GlcNAc-branched complex N-glycans, the high-
affinity ligands of galectin-3, on v and 3 integrin subunits 
with a concomitant inhibition of galectin-3–, VEGF-, and FGF-
induced angiogenesis in vitro as well as in vivo.
Integrin-mediated events, such as cell adhesion and migra-
tion, are regulated by integrin clustering and resulting activation 
of intracellular signaling pathways (Giancotti and Ruoslahti, 
1999). Numerous studies have speculated that galectin-3 has 
the potential to cluster integrins. Here, we directly demon-
strate that galectin-3–induces clustering of v3 integrins. 
Furthermore, we show that galectin-3–mediated clustering of 
integrin v3 promotes FAK activation, a key signaling step in 
the process of angiogenesis.
From these data, we propose the following model for   
galectin-3–mediated angiogenesis: galectin-3 CRD binds to 
GnTV-modified N-glycans on v3 integrin, and as a multi-
mer, it cross-links and clusters the integrin and activates FAK-
mediated signaling pathways that modulate events such as 
endothelial cell migration in the angiogenesis cascade. How 
might the carbohydrate-based galectin-3–integrin interaction 
fit into the cascade of events in the growth factor–mediated 
angiogenesis? It is thought that during angiogenesis, the ECM in 
contact with endothelial cells provides the necessary support for   
cytokine-mediated migration and capillary lumen formation 
(Kalluri, 2003). This support stems from the synergistic effects 
of cytokines and endothelial cell surface integrins (Eliceiri, 
2001). As described earlier, it is well established that growth 
factor-induced angiogenesis depends on specific integrins and 
antagonists  of  integrin  v3  effectively  inhibit  VEGF-  and 
bFGF-mediated  angiogenesis  in  vitro  and  in  vivo  (Brooks, 
1994, 1996; Drake et al., 1995; Friedlander et al., 1995; Storgard 
et al., 1999). Accordingly, we propose that in a dynamic ECM 
of endothelial cells undergoing angiogenesis, galectin-3 pro-
motes clustering and activation of integrins and, this in turn, fa-
cilitates  VEGF/bFGF-induced  angiogenesis.  Regarding  the 
mechanism that mediates cross-talk between growth factors and 
integrins, it is known that one form of such cross-talk involves 
galectin-3 in HUVECs by siRNA and knockdown of high-
affinity ligands of galectin-3 by silencing GnTV substantially 
reduced the growth factor–mediated angiogenesis in vitro. 
Furthermore, in the in vivo corneal micropocket assay, the 
extent of angiogenesis induced by VEGF and bFGF was sig-
nificantly less in Gal3/ mice compared with the Gal3+/+ ani-
mals. Together, these data conclusively establish that galectin-3 
significantly influences VEGF- and bFGF-mediated angio-
genesis. To our knowledge, this is the first demonstration of a 
defect in vascular response of Gal3/ mice.
In this paper, we also demonstrate that galectin-3 pro-
motes angiogenesis by interacting with complex N-glycans on 
v3 integrin and activating integrin signaling pathways that 
influence VEGF and bFGF angiogenic activity. Transmem-
brane integrin receptors are well known for their role in mod-
ulating angiogenesis (Brooks, 1996; Eliceiri and Cheresh, 
2001;  Stupack  and  Cheresh,  2004;  Mahabeleshwar  et  al., 
2006). Integrin v3, a major vitronectin receptor on endo-
thelial cells, plays a particularly important role in the cascade 
of events leading to the angiogenic response. Normally 
expressed in low levels, the expression of integrin v3 is up-
regulated in angiogenic vessels (Brooks, 1994, 1996; Storgard 
et al., 1999). The disruption of the function of v3 integrin 
with  antibodies  or  peptide  antagonists  effectively  inhibits 
VEGF- and bFGF-induced angiogenesis in vitro and in vivo 
(Brooks, 1994, 1996; Drake et al., 1995; Friedlander et al., 
1995; Storgard et al., 1999). It is thought that integrin v3 
influences cytokine-mediated angiogenesis by arbitrating   
vitronectin-mediated cell–matrix interactions that promote the 
following: enhanced expression of cytokine receptors, includ-
ing VEGFR; EC migration; and VEGF- and bFGF-induced 
signaling leading to angiogenesis. Integrin v3 also directly 
associates with cytokine receptors to enhance pro-angiogenic 
action of VEGF and bFGF, through a mechanism that is not 
fully understood (Brooks et al., 1994; Soldi et al., 1999).
Traditionally, functions of most integrins have been inves-
tigated in the context of protein–protein interactions (Hynes, 
2002; Guo and Giancotti, 2004; Lock et al., 2008). However, 
almost all integrins are glycosylated, and in recent years several 
studies have revealed that integrin glycans can modulate the 
transmembrane  signaling  (for  reviews  see  Bellis,  2004;  Gu   
et al., 2004). For example, 1,6GlcNAc-branched complex 
N-glycans synthesized by a glycosyltransferase, GnTV enzyme, 
have been shown to modulate 51 integrin-dependent “inside- 
out” and “outside-in” signaling during cancer cell migration 
(Guo et al., 2005; Lagana et al., 2006). To date, relatively few 
studies have focused on the role of galectin-3–mediated   
carbohydrate interactions in modulating specifically integrin 
signaling. Lagana et al. (2006) have reported that in carcinoma 
cells, galectin-3 interactions with GnTV-modified N-glycans 
stimulate 51-integrin activation and fibronectin-dependent 
tumor cell spreading and motility. Likewise, Goetz et al. (2008) 
have reported that galectin-3–mediated activation of 1 integ-
rin recruits tyrosine-phosphorylated Cav1, which stabilizes focal 
adhesions and regulates cell motility. Recent studies in our 
laboratory have also suggested that galectin-3 promotes epithelial 1990 Galectin-3 influences VEGF and bFGF-mediated angiogenesis | Markowska et al.
at Tufts University. The investigation conformed to the Association for 
Research in Vision and Ophthalmology Resolution on the Use of Animals 
in Vision Research and recommendations of the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. The corneal 
micropocket  angiogenesis  assay  was  performed  as  described  previously   
using implants containing a test agent, hydron, and sucralfate (Kenyon et al., 
1996). Test agents included full-length galectin-3 (0.25–2 mg/ml), Gal3C 
(1 mg/ml), VEGF (2.5 mg/ml), and bFGF (0.25 mg/ml). Implants con-
taining hydron and sucralfate alone served as negative controls. For micro-
pocket  assays,  6–8-wk-old  mice  were  anesthetized  by  intraperitoneal 
injection of a cocktail of ketamine (90–120 mg/kg) and xylazine (10 mg/kg). 
The eyes were topically anesthetized with proparacaine and were gently 
proptosed with forceps. With a use of a corneal blade and a stereoscope, 
and intrastromal linear keratomy was performed 2 mm from the limbus. 
Using a von Graefe knife (Miltex), a pocket was extended toward the limbus, 
and the pellet was maneuvered into the pocket. The wound was coated 
with a veterinary ophthalmical ointment to prevent infection. To quanti-
tate the extent of angiogenesis, on day 5 after surgery, the animals were 
anesthetized, corneas were photographed, and the vessel area was calcu-
lated using a formula PD × VL × CN × 0.628, where PD is the distance 
of the pellet from the limbal vein, VL is length of vessels, and CN is cir-
cumferential neovascularity. Alternatively, anesthetized animals were in-
jected intracardially with 100 µl of 5 mg/ml of FITC-BS1 to visualize the 
newly formed vessels. After 30 min, the animals were sacrificed, the eyes 
were fixed with 0.1% paraformaldehyde, and the flat mounts of the dis-
sected corneas were evaluated by fluorescence microscopy (Pola et al., 
2001). The total area of corneal neovascularization was calculated using 
ImageJ (NIH; http://rsb.info.nih.gov/nih-imageJ).
Modified Boyden chamber migration assay. The assay was performed as 
previously described (Leavesley et al., 1993). In brief, HUVECs were serum 
starved overnight in endothelial cell basal medium (EBM-2). Transwell   
inserts (8 µm pore size; Corning) were coated with 10 µg/ml of fibronectin 
and 5 × 104 HUVECs in 100 µl of EBM-2 were added to the upper chamber. 
The bottom chamber was filled with 600 µl of EBM-2 in the presence and 
absence of 10 ng/ml bFGF, 25 ng/ml VEGF, 10 µg/ml full-length galectin-3, 
or Gal3C. To assess the impact of CRD of galectin-3 on VEGF- and bFGF-
mediated angiogenesis, the experiments were preformed in the presence   
of saccharides (0.1 M -lactose and 0.1 M sucrose) and 10 µg/ml Gal3C.   
To determine the role of integrin v3 in galectin-3–mediated angiogenesis, 
experiments were performed in the presence of galectin-3 and functional-
blocking mAbs against human v (clone AV1), 3 (clone B3A), and v3 
(clone LM609). After 6-h incubation at 37°C, in a CO2 incubator, the cells 
were fixed and stained using the Diff-Quik staining kit (Dade-Behring). The 
nonmigrating cells (upper chamber) were removed with a cotton swab, and 
the migrating cells (bottom chamber) were manually counted in three non-
overlapping fields. Assays performed with media alone in the bottom chamber 
served as a negative control. Cell viability in the presence of various sub-
stances was tested by a trypan blue exclusion test.
Capillary tubule formation assay. The capillary tubule formation assay 
was performed as previously described (Nangia-Makker et al., 2000). In 
brief, HUVECs were plated on matrigel-coated 8 chamber slides (2 × 105 
cells/chamber) in the presence and absence of various test substances de-
scribed in the previous section for the cell migration assay. After 6 h of incu-
bation in a CO2 incubator, cells were photographed. To quantitate the data, 
the number of branch points in four nonoverlapping fields was determined.
Transfection of HUVECs with siRNA. Galectin-3 expression was re-
duced  by  transfection  with  siRNA  duplexes  directed  against  galectin-3 
(NCBI Protein Database accession no. NM_002306). For transfection, 3 × 
105 cells cultured in wells of a 6-well plate to 90% confluence were treated 
with 375 pmol of siRNA duplexes using 8 µl of Oligofectamine and OPTI-
MEM (8 µl oligofectamine/200 µl Opti-MEM/well). After 18 h incuba-
tion with siRNA, gene silencing was examined by RT-qPCR and Western 
physical interaction between the two classes of proteins. Specif-
ically, it has been reported that VEGFR2 binds to v3 integ-
rin (Soldi et al., 1999; Borges et al., 2000; Eliceiri, 2001; Eliceiri 
and Cheresh, 2001), and this binding occurs via the extracellular 
domain of the integrin and enhances the activity of the growth 
factor receptor (Borges et al., 2000). The biochemical interac-
tions that mediate the binding of VEGFR2 with the integrins 
have not been elucidated. It is tempting to speculate that oligo-
meric galectin-3 may promote such interactions by binding to 
GnTV-modified N-glycans on v3 integrin and VEGFR2. 
In this respect, it is known that the presence of N-glycans on 
VEGFR is required for its function (Vaisman et al., 1990) and, 
in a recent preliminary study, we have observed that galectin-3 
interacts with VEGFR2 (unpublished data). Thus, it is possible 
that galectin-3 may influence angiogenesis by alternative mech-
anisms involving clustering of VEGFR2 leading to the reduc-
tion in the receptor endocytosis and augmenting signaling or 
promoting interactions between the VEGFR2 and integrins. 
Studies to determine whether galectin-3 influences angiogene-
sis by cross-linking and modulating endocytosis of VEGFR2 
and/or promoting interactions between VEGFR2 and integ-
rins are currently underway in our laboratory.
In summary, the results of this study show that galectin-3 
is an important contributor to VEGF- and bFGF- mediated 
angiogenesis. These findings have broad implications for de-
veloping  novel,  carbohydrate-based  therapeutic  agents  for 
inhibition of angiogenesis.
MATERIALS AND METHODS
Materials and cell culture. HUVECs were provided by V. Sukhatme (Beth 
Israel Deaconess Medical Center, Boston, MA). The cells were maintained in 
endothelial cell growth medium (EGM-2; Lonza) and were used between 
passages 3 to 8). Purified full-length recombinant galectin-3 was prepared as 
described earlier (Hsu et al., 1992). Gal3C was prepared by collagenase treat-
ment of full-length galectin-3 as described by John et al. (2003). Recombinant 
VEGF-A was obtained from Cell Sciences and R&D Systems. Growth factor–
reduced matrigel, anti-integrin v and 3 mAbs, and anti-FAK and pFAK 
were obtained from BD. Function-blocking mAbs directed against v, 3, 
and v3 were obtained from Millipore. All lectins and anti–mouse IgG and 
anti–rabbit IgG secondary antibodies were obtained from Vector Laboratories. 
FITC-anti–mouse IgG was obtained from Jackson Immunoresearch Laborato-
ries. Hybridoma, M3/38, expressing monoclonal anti-galectin-3 antibody was 
obtained from American Type Culture Collection. RNeasy kit was purchased 
from QIAGEN. High Capacity cDNA Archive kit, qPCR master mix, and 
qPCR primers were purchased from Applied Biosystems. All siRNA du-
plexes were from Thermo Fisher Scientific. Oligofectamine and Opti-MEM   
were obtained from Invitrogen. EZ-Link-sulfo-NHS-LC-Biotin and 3,3- 
Dithiobis(sulfosuccinimidylpropionate) were purchased from Thermo Fisher 
Scientific. All other reagents were obtained from Sigma-Aldrich.
Animals. In this study, we used 6–8-wk-old Gal3+/+, Gal3/, GnTV/, 
and GnTV+/+ mice. Gal3/ mice were generated by targeted interruption 
of the galectin-3 gene, as described previously (Hsu et al., 2000). Gal3+/+ 
and Gal3/ mice were obtained by interbreeding Gal3+/ mice and carried 
as separate lineages. GnTV animals, generated by Dennis and collaborators 
(Granovsky et al., 2000), were obtained from the Consortium for Functional 
Glycomics (The Scripps Research Institute).
Corneal mouse micropocket angiogenesis assay. All animal proce-
dures were approved by the Institutional Animal Care and Use Committee JEM VOL. 207, August 30, 2010 
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recently published procedure (Saravanan et al., 2009). The clone selected 
was: TRCN0000036061. The extent of GnTV knockdown at the mRNA 
level was assessed by RT-qPCR as described above using inventory gene-
specific primers (GnTV: Hs00159136_m1 and GAPDH: Hs99999905_m). 
The knockdown of 1–6GlcNAc-branched chains, the product of GnTV, 
was detected by staining with rhodamine-conjugated l-PHA lectin.
Analysis of galectin-3 interaction with GnTV glycans on endothelial 
cell surface. Both control and GnTV knockdown HUVECs were lifted 
from the plate by incubation with 5mM EDTA and resuspended in PBS (25 × 
106 cell/ml). Cell surface proteins were biotinylated and cross-linked in one-
step procedure by incubation with 0.5mg EZ-Link-sulfo-NHS-LC-Biotin and 
0.1mg 3,3-Dithiobis(sulfosuccinimidylpropionate), as described by Altin et al. 
(Altin and Pagler, 1995). After incubation, the cells were washed with cold PBS 
and lysed with TNTE lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
1% Triton-X100, 1 mM EDTA). Aliquots of cell lysates (0.5mg of protein) 
were precleared with 25 µg packed Sepharose 4B beads (1 h at 4°C) and incu-
bated with streptavidin agarose CL-4B (1 h at 4°C). The streptavidin bound 
proteins were released by boiling the beads for 5 min in the Laemmli sample 
buffer, separated on 4–20% SDS-PAGE gels in reducing conditions, transferred 
onto a nitrocellulose membrane and probed for galectin-3 as described earlier.
Analysis of v3 integrin glycans. To determine whether 1,6GlcNAc-
branched glycans are present on v and 3 integrin subunits and, if so, whether 
they are reduced in the GnTV knockdown cells, RIPA buffer lysates of un-
treated, control shRNA- and GnTV shRNA–transfected HUVECs were incu-
bated with 20 µl of unconjugated Sepharose 4B (1 h at 4°C) to reduce nonspecific 
binding. Unbound proteins were then incubated with 30 µl agarose-conjugated 
l-PHA or Con A for 1 h at 4°C. The beads were subsequently washed and the 
proteins bound to the beads were released by boiling in SDS sample buffer and 
separated on 12% SDS-PAGE gel. Protein blots of the gels were processed for 
immunostaining using anti-human v and 3 integrin mAbs as described above.
Statistical analyses. Data are expressed as mean ± SEM. Statistical signifi-
cance was determined using a two-tailed Student’s t-test.
Online supplemental material. Fig. S1 shows MALDI-TOF MS analysis 
peptide matches for integrin v and 3 in the fraction eluted with lactose 
from the galectin-3 affinity column. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20090121/DC1.
The authors thank Dr. Marsha Moses for helpful comments and Catherine 
Butterfield for help with the mouse corneal micropocket assay. MALDI-TOF mass 
spectrometry was performed by Dr. Ian Rawe (The Schepens Eye Research Institute, 
Boston, MA). We also thank Dr. Hakon Leffler for galectin-3 constructs.
This work was supported by the National Eye Institute Grant EY007088  
(N. Panjwani), R01AI20958 (F.T. Liu), the New England Corneal Transplant Fund, the 
Mass Lions Eye Research fund, and a challenge grant from Research to Prevent 
Blindness. GnTV animals were kindly provided by the Consortium for Functional 
Glycomics (La Jolla, California; grant number National Institutes of Health 
GM62116). Confocal microscopy was performed at the Tufts Center for 
Neuroscience Research Core facility supported by NIH grant P30 NS047243).
The authors have no conflicting financial interests.
Submitted: 15 January 2009
Accepted: 8 July 2010
REFERENCES
Ahmad, N., H.J. Gabius, S. André, H. Kaltner, S. Sabesan, R. Roy, B. 
Liu, F. Macaluso, and C.F. Brewer. 2004. Galectin-3 precipitates as 
a pentamer with synthetic multivalent carbohydrates and forms het-
erogeneous cross-linked complexes. J. Biol. Chem. 279:10841–10847. 
doi:10.1074/jbc.M312834200
Altin,  J.G.,  and  E.B.  Pagler.  1995.  A  one-step  procedure  for  biotinylation 
and  chemical  cross-linking  of  lymphocyte  surface  and  intracellular   
blotting. Control cells were treated with a nontargeting siRNA duplex (no. 
D-001210-02-05).
For RT-qPCR, RNeasy kit was used to isolate total RNA, and cDNA was 
synthesized using the High Capacity cDNA Archive kit. PCR was performed in 
triplicates according to the manufacturer’s instructions using cDNA, inventory 
gene-specific primers (Gal3, Hs00173587_m1; GAPDH, Hs99999905_m; Ap-
plied Biosystems Inc.), and master mix containing ROX as a passive reference. 
Reactions performed in the absence of template served as the negative control. 
Quantification data of each gene were normalized to the expression of GAPDH, 
which served as a positive amplification control. A value of 1.0 was assigned to 
the expression of each gene in the untransfected HUVECs which served as a 
calibrator. The expression values for galectin-3 knockdown HUVECs were cal-
culated as change in expression level with respect to untransfected HUVECs.
For Western blot analysis, radioimmunoprecipitation (RIPA) buffer ex-
tracts of siRNA-transfected and control cell lysates were electrophoresed on 
a 4–20% SDS-PAGE gel. Protein blots of the gel were processed for immuno-
staining using monoclonal anti-galectin-3 (M3/38) and monoclonal -actin 
(1:20,000) as primary antibodies; HRP-conjugated anti-rat IgG (1:50,000) 
and HRP-conjugated anti-mouse IgG (1:50,000) as secondary antibodies; 
and a chemiluminescence detection system. The intensity of the bands was 
quantified using ImageJ.
Isolation of galectin-3 binding proteins of HUVECs. Galectin-3 bind-
ing proteins were isolated by chromatography of HUVEC cell extracts on a 
galectin-3 affinity column as described earlier (Saravanan et al., 2009). Proteins 
bound to the affinity column were eluted using PBS containing 0.1% Tween-20 
(PBST) and 0.1 M -lactose, and were resolved by electrophoresis in reducing 
10% SDS-PAGE gels. Coomassie blue–stained components detected on the 
gel were subjected to peptide analysis using a prO-TOF 2000 MALDI-TOF 
mass spectrometer. In some experiments, to confirm sugar binding specificity 
of the galectin-3–binding proteins, before elution with -lactose, the column 
was eluted with PBST containing 0.1 M sucrose. The identity of galectin-3–
binding proteins of interest, specifically v and 3 integrin subunits, was   
also confirmed by immunoblot analysis using monoclonal anti-integrin v 
(1:250) and anti-integrin 3 (1:500) as primary antibodies and HRP-conjugated 
anti–mouse IgG (1:50,000) as a secondary antibody.
Integrin  v3  clustering.  HUVECs  were  plated  in  8-chamber  slides 
coated with 10 µg/ml fibronectin at the density of 104 cells/chamber. The 
cells were serum starved overnight in EBM-2, and then treated with 10 µg/
ml galectin-3 for 10 min. Subsequently, the cells were fixed with 4% para-
formaldehyde in PBS (10 min at 37°C), treated with 1% BSA in PBS (1 h at 
37°C) to block nonspecific binding sites, and then sequentially incubated 
with 10 µg/ml anti-integrin v3 mAb in blocking buffer (1 h at room 
temperature) and FITC-anti–mouse IgG (1:200; 1 h at room temperature). 
The slides were mounted using Vectashield mounting medium (Vector Lab-
oratories) and viewed with a 20× objective lens (Carl Zeiss, Inc.) on a DMR 
confocal laser fluorescence microscope (Leica). Images were generated using 
the Leica Confocal Software at a resolution of 1024 × 1024 pixels.
FAK activation. HUVECs (70% confluence) were serum starved for 2 h in 
EBM-2 basal media and were then treated with 10 µg/ml galectin-3 for 30 s,   
1, 2, 5, and 10 min. RIPA buffer lysates of the lectin-treated cells were sepa-
rated on 4–20% SDS-PAGE gels, and protein blots of the gels were sub-
jected to Western blot analysis using rabbit anti-pFAK mAb (1:1,000; clone 
141–9; 2 h at room temperature) and HRP-conjugated anti–rabbit IgG sec-
ondary antibody (1:20,000; 1 h at room temperature). For detection of total 
FAK, the blots were sequentially incubated with mouse anti-FAK mAb 
(1:1,000; clone 77; 2 h at room temperature) and HRP-conjugated anti–
mouse IgG secondary antibody (1:50,000, 1 h at room temperature). Immu-
nostained components were then visualized by a chemiluminescence detection 
system. All antibodies were diluted in the blocking buffer.
Silencing of GnTV Gene Expression in HUVECs. Stable short hairpin 
RNA (shRNA) cell lines targeting GnTV were generated according to our 1992 Galectin-3 influences VEGF and bFGF-mediated angiogenesis | Markowska et al.
Hirabayashi,  J.,  T.  Hashidate,  Y.  Arata,  N.  Nishi,  T.  Nakamura,  M. 
Hirashima, T. Urashima, T. Oka, M. Futai, W.E. Muller, et al. 2002. 
Oligosaccharide specificity of galectins: a search by frontal affinity chro-
matography. Biochim. Biophys. Acta. 1572:232–254.
Hodivala-Dilke, K.M., A.R. Reynolds, and L.E. Reynolds. 2003. Integrins 
in angiogenesis: multitalented molecules in a balancing act. Cell Tissue 
Res. 314:131–144. doi:10.1007/s00441-003-0774-5
Hsu, D.K., R.I. Zuberi, and F.T. Liu. 1992. Biochemical and biophysical 
characterization of human recombinant IgE-binding protein, an S-type 
animal lectin. J. Biol. Chem. 267:14167–14174.
Hsu, D.K., R.Y. Yang, Z. Pan, L. Yu, D.R. Salomon, W.P. Fung-Leung, 
and F.T. Liu. 2000. Targeted disruption of the galectin-3 gene re-
sults in attenuated peritoneal inflammatory responses. Am. J. Pathol. 
156:1073–1083.
Hynes, R.O. 2002. Integrins: bidirectional, allosteric signaling machines. 
Cell. 110:673–687. doi:10.1016/S0092-8674(02)00971-6
Ilic, D., Y. Furuta, S. Kanazawa, N. Takeda, K. Sobue, N. Nakatsuji, S. 
Nomura, J. Fujimoto, M. Okada, and T. Yamamoto. 1995. Reduced 
cell motility and enhanced focal adhesion contact formation in cells from 
FAK-deficient mice. Nature. 377:539–544. doi:10.1038/377539a0
Ilic, D., B. Kovacic, K. Johkura, D.D. Schlaepfer, N. Tomasević, Q. Han, 
J.B. Kim, K. Howerton, C. Baumbusch, N. Ogiwara, et al. 2004. FAK 
promotes  organization  of  fibronectin  matrix  and  fibrillar  adhesions.  
J. Cell Sci. 117:177–187. doi:10.1242/jcs.00845
John, C.M., H. Leffler, B. Kahl-Knutsson, I. Svensson, and G.A. Jarvis. 
2003. Truncated galectin-3 inhibits tumor growth and metastasis in or-
thotopic nude mouse model of human breast cancer. Clin. Cancer Res. 
9:2374–2383.
Kalluri, R. 2003. Basement membranes: structure, assembly and role in tu-
mour angiogenesis. Nat. Rev. Cancer. 3:422–433. doi:10.1038/nrc1094
Kenyon, B.M., E.E. Voest, C.C. Chen, E. Flynn, J. Folkman, and R.J. 
D’Amato. 1996. A model of angiogenesis in the mouse cornea. Invest. 
Ophthalmol. Vis. Sci. 37:1625–1632.
Koch, A.E. 1998. Review: angiogenesis: implications for rheumatoid ar-
thritis. Arthritis Rheum. 41:951–962. doi:10.1002/1529-0131(199806) 
41:6<951::AID-ART2>3.0.CO;2-D
Kulkarni, A.D., and B.D. Kuppermann. 2005. Wet age-related macular de-
generation. Adv. Drug Deliv. Rev. 57:1994–2009. doi:10.1016/j.addr 
.2005.09.003
Lagana, A., J.G. Goetz, P. Cheung, A. Raz, J.W. Dennis, and I.R. Nabi. 
2006. Galectin binding to Mgat5-modified N-glycans regulates fibro-
nectin matrix remodeling in tumor cells. Mol. Cell. Biol. 26:3181–3193. 
doi:10.1128/MCB.26.8.3181-3193.2006
Leavesley, D.I., M.A. Schwartz, M. Rosenfeld, and D.A. Cheresh. 1993. 
Integrin beta 1- and beta 3-mediated endothelial cell migration is trig-
gered through distinct signaling mechanisms. J. Cell Biol. 121:163–170. 
doi:10.1083/jcb.121.1.163
Lock, J.G., B. Wehrle-Haller, and S. Strömblad. 2008. Cell-matrix adhesion 
complexes: master control machinery of cell migration. Semin. Cancer 
Biol. 18:65–76. doi:10.1016/j.semcancer.2007.10.001
Mahabeleshwar, G.H., W. Feng, D.R. Phillips, and T.V. Byzova. 2006. 
Integrin signaling is critical for pathological angiogenesis. J. Exp. Med. 
203:2495–2507. doi:10.1084/jem.20060807
Matarrese, P., O. Fusco, N. Tinari, C. Natoli, F.T. Liu, M.L. Semeraro, W. 
Malorni, and S. Iacobelli. 2000. Galectin-3 overexpression protects from 
apoptosis by improving cell adhesion properties. Int. J. Cancer. 85:545–
554. doi:10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17> 
3.0.CO;2-N
Nangia-Makker, P., Y. Honjo, R. Sarvis, S. Akahani, V. Hogan, K.J. Pienta, 
and A. Raz. 2000. Galectin-3 induces endothelial cell morphogenesis 
and angiogenesis. Am. J. Pathol. 156:899–909.
Nangia-Makker, P., V. Hogan, Y. Honjo, S. Baccarini, L. Tait, R. Bresalier, 
and A. Raz. 2002. Inhibition of human cancer cell growth and metasta-
sis in nude mice by oral intake of modified citrus pectin. J. Natl. Cancer 
Inst. 94:1854–1862.
Ohannesian, D.W., D. Lotan, P. Thomas, J.M. Jessup, M. Fukuda, H.J. 
Gabius, and R. Lotan. 1995. Carcinoembryonic antigen and other gly-
coconjugates act as ligands for galectin-3 in human colon carcinoma 
cells. Cancer Res. 55:2191–2199.
membrane-associated molecules. Anal. Biochem. 224:382–389. doi:10 
.1006/abio.1995.1054
Bellis,  S.L.  2004.  Variant  glycosylation:  an  underappreciated  regulatory 
mechanism  for  beta1  integrins.  Biochim.  Biophys.  Acta.  1663:52–60. 
doi:10.1016/j.bbamem.2004.03.012
Borges, E., Y. Jan, and E. Ruoslahti. 2000. Platelet-derived growth factor 
receptor beta and vascular endothelial growth factor receptor 2 bind 
to the beta 3 integrin through its extracellular domain. J. Biol. Chem. 
275:39867–39873. doi:10.1074/jbc.M007040200
Braren, R., H. Hu, Y.H. Kim, H.E. Beggs, L.F. Reichardt, and R. Wang. 
2006. Endothelial FAK is essential for vascular network stability, cell 
survival, and lamellipodial formation. J. Cell Biol. 172:151–162. doi:10 
.1083/jcb.200506184
Breier, G. 2000. Angiogenesis in embryonic development—a review. 
Placenta. 21:S11–S15. doi:10.1053/plac.1999.0525
Brooks,  P.C.  1996.  Role  of  integrins  in  angiogenesis.  Eur.  J.  Cancer. 
32:2423–2429. doi:10.1016/S0959-8049(96)00381-4
Brooks, P.C., R.A. Clark, and D.A. Cheresh. 1994. Requirement of vascu-
lar integrin alpha v beta 3 for angiogenesis. Science. 264:569–571. doi:10 
.1126/science.7512751
Carmeliet, P., and R.K. Jain. 2000. Angiogenesis in cancer and other dis-
eases. Nature. 407:249–257. doi:10.1038/35025220
Cross, M.J., and L. Claesson-Welsh. 2001. FGF and VEGF function in 
angiogenesis: signalling pathways, biological responses and therapeu-
tic inhibition. Trends Pharmacol. Sci. 22:201–207. doi:10.1016/S0165- 
6147(00)01676-X
Cummings, R.D., and S. Kornfeld. 1982. Characterization of the structural 
determinants required for the high affinity interaction of asparagine-linked 
oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating 
and erythroagglutinating lectins. J. Biol. Chem. 257:11230–11234.
Dong, S., and R.C. Hughes. 1997. Macrophage surface glycoproteins binding 
to galectin-3 (Mac-2-antigen). Glycoconj. J. 14:267–274. doi:10.1023/ 
A:1018554124545
Drake, C.J., D.A. Cheresh, and C.D. Little. 1995. An antagonist of integrin 
alpha v beta 3 prevents maturation of blood vessels during embryonic 
neovascularization. J. Cell Sci. 108:2655–2661.
Eliceiri, B.P. 2001. Integrin and growth factor receptor crosstalk. Circ. Res. 
89:1104–1110. doi:10.1161/hh2401.101084
Eliceiri, B.P., and D.A. Cheresh. 2001. Adhesion events in angiogenesis. Curr. 
Opin. Cell Biol. 13:563–568. doi:10.1016/S0955-0674(00)00252-0
Fraser, H.M., and S.F. Lunn. 2000. Angiogenesis and its control in the fe-
male  reproductive  system.  Br.  Med.  Bull.  56:787–797.  doi:10.1258/ 
0007142001903364
Friedlander, M., P.C. Brooks, R.W. Shaffer, C.M. Kincaid, J.A. Varner, 
and D.A. Cheresh. 1995. Definition of two angiogenic pathways by 
distinct alpha v integrins. Science. 270:1500–1502. doi:10.1126/science 
.270.5241.1500
Gardner,  T.W.,  D.A.  Antonetti,  A.J.  Barber,  K.F.  LaNoue,  and  S.W. 
Levison. 2002. Diabetic retinopathy: more than meets the eye. Surv. 
Ophthalmol. 47:S253–S262. doi:10.1016/S0039-6257(02)00387-9
Giancotti, F.G., and E. Ruoslahti. 1999. Integrin signaling. Science. 285:1028– 
1032. doi:10.1126/science.285.5430.1028
Goetz, J.G., B. Joshi, P. Lajoie, S.S. Strugnell, T. Scudamore, L.D. Kojic, and I.R. 
Nabi. 2008. Concerted regulation of focal adhesion dynamics by galectin-3 
and tyrosine-phosphorylated caveolin-1. J. Cell. Biol. 180:1261–1275.
Granovsky, M., J. Fata, J. Pawling, W.J. Muller, R. Khokha, and J.W. 
Dennis. 2000. Suppression of tumor growth and metastasis in Mgat5-
deficient mice. Nat. Med. 6:306–312. doi:10.1038/73163
Gu, Y.C., T.R. Bauer Jr., M.R. Ackermann, C.W. Smith, M.E. Kehrli 
Jr., M.F. Starost, and D.D. Hickstein. 2004. The genetic immunodefi-
ciency disease, leukocyte adhesion deficiency, in humans, dogs, cattle, 
and mice. Comp. Med. 54:363–372.
Guo, W., and F.G. Giancotti. 2004. Integrin signalling during tumour pro-
gression. Nat. Rev. Mol. Cell Biol. 5:816–826. doi:10.1038/nrm1490
Guo, H.B., I. Lee, B.T. Bryan, and M. Pierce. 2005. Deletion of mouse 
embryo  fibroblast  N-acetylglucosaminyltransferase  V  stimulates   
alpha5beta1  integrin  expression  mediated  by  the  protein  kinase  C 
signaling  pathway.  J.  Biol.  Chem.  280:8332–8342.  doi:10.1074/jbc 
.M413532200JEM VOL. 207, August 30, 2010 
Article
1993
Parsons, J.T. 2003. Focal adhesion kinase: the first ten years. J. Cell Sci. 
116:1409–1416. doi:10.1242/jcs.00373
Partridge, E.A., C. Le Roy, G.M. Di Guglielmo, J. Pawling, P. Cheung, M. 
Granovsky, I.R. Nabi, J.L. Wrana, and J.W. Dennis. 2004. Regulation 
of cytokine receptors by Golgi N-glycan processing and endocytosis. 
Science. 306:120–124. doi:10.1126/science.1102109
Pola,  R.,  L.E.  Ling,  M.  Silver,  M.J.  Corbley,  M.  Kearney,  R.  Blake 
Pepinsky, R. Shapiro, F.R. Taylor, D.P. Baker, T. Asahara, and J.M. 
Isner. 2001. The morphogen Sonic hedgehog is an indirect angiogenic 
agent upregulating two families of angiogenic growth factors. Nat. Med. 
7:706–711. doi:10.1038/89083
Price, M.O., R.W. Thompson Jr., and F.W. Price Jr. 2003. Risk factors 
for various causes of failure in initial corneal grafts. Arch. Ophthalmol. 
121:1087–1092. doi:10.1001/archopht.121.8.1087
Saravanan, C., F.T. Liu, I.K. Gipson, and N. Panjwani. 2009. Galectin-3 
promotes lamellipodia formation in epithelial cells by interacting with 
complex N-glycans on alpha3beta1 integrin. J. Cell Sci. 122:3684–3693. 
doi:10.1242/jcs.045674
Shen, T.L., A.Y. Park, A. Alcaraz, X. Peng, I. Jang, P. Koni, R.A. Flavell, 
H. Gu, and J.L. Guan. 2005. Conditional knockout of focal adhesion 
kinase in endothelial cells reveals its role in angiogenesis and vascular 
development in late embryogenesis. J. Cell Biol. 169:941–952. doi:10 
.1083/jcb.200411155
Soldi,  R.,  S.  Mitola,  M.  Strasly,  P.  Defilippi,  G.  Tarone,  and  F. 
Bussolino.  1999.  Role  of  alphavbeta3  integrin  in  the  activation  of 
vascular endothelial growth factor receptor-2. EMBO J. 18:882–892. 
doi:10.1093/emboj/18.4.882
Stillman, B.N., D.K. Hsu, M. Pang, C.F. Brewer, P. Johnson, F.T. Liu, and 
L.G. Baum. 2006. Galectin-3 and galectin-1 bind distinct cell surface gly-
coprotein receptors to induce T cell death. J. Immunol. 176:778–789.
Storgard, C.M., D.G. Stupack, A. Jonczyk, S.L. Goodman, R.I. Fox, and 
D.A. Cheresh. 1999. Decreased angiogenesis and arthritic disease in rab-
bits treated with an alphavbeta3 antagonist. J. Clin. Invest. 103:47–54. 
doi:10.1172/JCI3756
Stupack, D.G., and D.A. Cheresh. 2004. Integrins and angiogenesis. Curr. 
Top. Dev. Biol. 64:207–238. doi:10.1016/S0070-2153(04)64009-9
Tonnesen, M.G., X. Feng, and R.A. Clark. 2000. Angiogenesis in wound 
healing. J. Investig. Dermatol. Symp. Proc. 5:40–46. doi:10.1046/j.1087-
0024.2000.00014.x
Vaisman, N., D. Gospodarowicz, and G. Neufeld. 1990. Characterization 
of the receptors for vascular endothelial growth factor. J. Biol. Chem. 
265:19461–19466.
Yang, E., J.S. Shim, H.J. Woo, K.W. Kim, and H.J. Kwon. 2007. Amino-
peptidase  N/CD13  induces  angiogenesis  through  interaction  with   
a pro-angiogenic protein, galectin-3. Biochem. Biophys. Res. Commun. 
363:336–341. doi:10.1016/j.bbrc.2007.08.179